Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.09 [0.55, 2.12]
4 studies · 1712 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.77 [0.39, 1.53]
4 studies · 1055 participants
Low